Official Title

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib
  • Phase

    Phase 2
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    dasatinib ...
  • Study Participants

The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia
Study Started
Apr 30
Primary Completion
Mar 31
Study Completion
Sep 30
Last Update
Sep 15

Drug dasatinib

100mg QD

  • Other names: BMS-354825

dasatinib Experimental


Inclusion Criteria:

Chronic Myeloid Leukemia in the Chronic Phase
20 years old over
ECOG performance status (PS) score 0-2
Patients for major molecular response (MMR) with no CMR
Adequate organ function (hepatic, renal and lung)
Signed written informed consent

Exclusion Criteria:

A case with the double cancer of the activity
Women who are pregnant or breastfeeding
The case of Pleural effusion clearly

Patients with complications or a history of severe or uncontrolled cardiovascular failure following

have a Myocardial infarction within 6 months
have an Angina within 3 months
have a Congestive heart failure within 3 months
have a suspected congenital QT syndrome
have a QTc interval of more than 450msec at baseline
A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy
Prior treatment with dasatinib
Subjects with T315I, F317L and V299L BCR-ABL point mutations
No Results Posted